Susquehanna International Group, LLP Puma Biotechnology, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.25 - $4.03 $119,250 - $213,590	-53,000 Reduced 75.5%	17,200 $43,000
Q2 2024 Aug 15, 2024	SELL	$2.92 - $5.83 $884,176 - $1.77 Million	-302,800 Reduced 81.18%	70,200 $228,000
Q1 2024 May 07, 2024	BUY	$4.29 - $7.4 $1.15 Million - $1.98 Million	268,100 Added 255.58%	373,000 $1.98 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $82,956 - $167,028	37,200 Added 54.95%	104,900 $454,000
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $93,365 - $145,195	35,500 Added 110.25%	67,700 $178,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $33,540 - $46,182	-12,900 Reduced 28.6%	32,200 $113,000
Q1 2023 May 16, 2023	SELL	$2.21 - $4.82 $125,970 - $274,740	-57,000 Reduced 55.83%	45,100 $139,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $101,336 - $242,824	47,800 Added 88.03%	102,100 $431,000
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $18,841 - $31,872	8,300 Added 18.04%	54,300 $129,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $37,884 - $76,230	23,100 Added 100.87%	46,000 $131,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $14,484 - $22,032	-6,800 Reduced 22.9%	22,900 $66,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $53,040 - $75,120	8,000 Added 36.87%	29,700 $208,000
Q2 2021 Aug 11, 2021	SELL	$8.98 - $11.6 $128,414 - $165,880	-14,300 Reduced 39.72%	21,700 $199,000
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $226,058 - $328,483	24,100 Added 202.52%	36,000 $350,000
Q4 2020 Feb 16, 2021	SELL	$7.78 - $12.13 $300,308 - $468,218	-38,600 Reduced 76.44%	11,900 $122,000
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $58,900 - $69,068	-6,200 Reduced 10.93%	50,500 $510,000
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $478,082 - $902,968	-68,200 Reduced 54.6%	56,700 $591,000
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $488,584 - $1.13 Million	77,800 Added 165.18%	124,900 $1.05 Million
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $445,250 - $735,005	-68,500 Reduced 59.26%	47,100 $412,000
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $141,750 - $208,170	16,200 Added 16.3%	115,600 $1.24 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $1.33 Million - $3.86 Million	-107,900 Reduced 52.05%	99,400 $1.26 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $2.64 Million - $5.39 Million	127,300 Added 159.13%	207,300 $8.04 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $471,645 - $1.1 Million	-23,500 Reduced 22.71%	80,000 $1.63 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $6.05 Million - $8.79 Million	-146,800 Reduced 58.65%	103,500 $4.75 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $6.57 Million - $9.28 Million	136,000 Added 118.99%	250,300 $14.8 Million
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $20.2 Million - $33.5 Million	-337,800 Reduced 74.72%	114,300 $7.78 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $14 Million - $19.7 Million	148,900 Added 49.11%	452,100 $44.7 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $21.8 Million - $36.3 Million	303,200	303,200 $36.3 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

Vanguard Group Inc Valley Forge, PA

3.64M
Shares

$10.9 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.57M
Shares

$10.7 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

3.06M
Shares

$9.19 Million
0.42% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.88M
Shares

$8.64 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.97M
Shares

$5.91 Million
0.02% of portfolio

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account